BAN2401 Phase 3 Clinical Trial Starting April 2019

MIAMI - March 21, 2019 - PRLog -- Dr. Victor Faradji, Neurologist at First Choice Neurology in Miami, Florida is enthusiastic about the results of the BAN2401 phase 2 clinical trial for dementia. The study assessed changes from baseline to 18 months in biomarkers measuring the underlying disease pathophysiology, including changes in amyloid accumulated in the brain as measured by amyloid PET. The clinical endpoints of Alzheimer's Disease Composite Score, Alzheimer's Disease Assessment Scale-cognitive subscale and Clinical Dementia Rating Sum of Boxes were also assessed from baseline to 18 months of treatment. In amyloid PET image visual read, BAN2401 demonstrated a dose-dependent conversion from amyloid positive to negative, and at the highest dose, 81% of patients converted from amyloid positive to negative at 18 months.

BAN2401 is a humanized monoclonal antibody for Alzheimer's disease that targets the protofibrils of beta-amyloid before they aggregate into amyloid plaques. BAN2401 may have the potential to have an effect on disease pathology and to slow down the progression of the disease.

Eisai and Biogen are offering patients to participate in the phase 3 study starting in April 2019. Dr. Victor Faradji of First Choice Neurology is one of the Principal Investigators of the BAN2401 clinical trial. Contact Nicole Good at 954-258-7389 to be considered in the BAN2401 phase 3 clinical trial for dementia. Or email Nicole at NGoood@vintrials.com

About Victor Faradji, MD
Victor Faradji, MD is Board Certified by the American Board of Psychiatry and Neurology.  He practices general adult and adolescent neurology with special interest in electromyography (EMG), neuromuscular and spinal disorders, migraine, vertigo, and Dementia.

Dr. Faradji has participated in many scientific research studies including diabetic neuropathy and the IDEAS study for Alzheimer's disease.

About First Choice Neurology
First Choice Neurology services patients with a variety of neurological conditions including Alzheimer's disease, dementia, epilepsy, migraines, multiple sclerosis, neuromuscular disorders, Parkinson's disease, sleep disorders, strokes, and more. They have several locations throughout Florida.

For more information about First Choice Neurology and the BAN2401 clinical trial, visit their website at https://www.fcneurology.net